Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 18Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Stomach Neoplasms 4Neoplasms 3Colorectal Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Carcinoma 2Adenocarcinoma 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1

Interventions

nimotuzumab 1gimeracil 1endostar protein 1Radiotherapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal × nimotuzumab × Clear all
NCT02591784 2022-03-17

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
42 enrolled
Gastrointestinal

Esophageal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡